This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Canine Parvovirus Therapeutic Antibody Development
Background of CPV
Canine parvovirus (CPV) is a highly contagious virus primarily affecting canines, particularly puppies, causing severe gastroenteritis. Given CPV's high contagiousness and potential fatality, researching targeted therapeutic strategies is crucial. BioVenic offers development services for therapeutic antibodies against canine parvovirus, assisting in creating effective monoclonal antibodies covering the entire process.
Background of CPV
| Full Name | Canine parvovirus |
|---|---|
| Aliases | CPV |
| Target Profile | CPV belongs to the Parvoviridae family and has a non-enveloped single-stranded DNA genome. It can survive in the external environment for extended periods and is commonly transmitted through direct contact with viral particles or environments contaminated with the virus, particularly through fecal matter. CPV primarily targets rapidly dividing cells, like intestinal epithelial cells and bone marrow cells, leading to severe diarrhea, vomiting, and immunosuppression in infected canines. |
MoA of CPV
The homodimeric transferrin receptor (TfR) is a primary receptor for CPV. Canine TfR has four glycosylations on the VP2 residues, and these amino acid changes enable CPV to attach to canine cells. CPV enters cells via clathrin-mediated endocytosis and is further transported to early endosomes, finally moving to lysosomes. In lysosomes, the release of VP1's PLA2 enzyme domain disrupts the lysosomal membrane, releasing CPV into the cytoplasmic sol. The virus is then transported to the nucleus, where its single-stranded DNA is replicated into double-stranded DNA and transcribed into mRNA to synthesize new viral proteins. This receptor-dependent nature of CPV allows the virus to specifically infect certain cell types. Its binding to the receptor is the first step in entering the host cell, a critical phase in the virus's lifecycle and a potential point for therapeutic intervention.
Fig.1 Schematic diagram of CPV replication.1,2
Application in Veterinary Therapeutics
Therapeutic antibodies against CPV are specifically designed to recognize and bind to the surface proteins of CPV, effectively preventing the virus from entering host cells. By neutralizing the virus, these antibodies reduce its replication and spread within the host, aiding in disease control. CPV infections often lead to severe gastrointestinal symptoms, such as vomiting and diarrhea. Therapeutic antibodies can alleviate these symptoms by reducing the viral load, increasing the animal's comfort and survival rate. Additionally, CPV infections can lead to complications, including dehydration and secondary infections. Therapeutic antibodies help reduce the risk of these complications by mitigating the severity of the primary infection.
Canine Parvovirus Therapeutic Antibody Development Services
BioVenic offers development services for therapeutic antibodies against CPV. Our team utilizes advanced technologies, such as hybridoma, single B cell, and phage display technologies, to prepare and screen high-specific antibodies that bind to CPV. We also provide comprehensive antibody characterization services, including structural and functional characterization. We are committed to assisting in the development of high-affinity therapeutic antibodies for companion animals, and thus we have established a species-specific antibody development platform to reduce heterologous components in the antibodies.
Please click the link below for more information about our canine CPV therapeutic antibody development services.
Fig.2 Antibody discovery and production methods: from mouse hybridoma to transgenic mice. (BioVenic Original)
Why Choose Us?
BioVenic provides a one-stop antibody development service, covering the entire process from antigen expression, animal immunization, antibody preparation, characterization, to engineering, offering a more convenient experience.
Our species-specific antibody development service, through antibody caninization and fully canine antibody development, reduces heterologous components in the antibodies to meet the specific therapeutic needs of canine patients.
Our professional team enforces strict quality control throughout the service process, ensuring that each step meets high quality, guaranteeing the optimal purity and stability of the veterinary therapeutic antibody samples.
Canine parvovirus infection progresses rapidly, with a short disease course and a high mortality rate. Using therapeutic antibodies for canine parvovirus can significantly improve recovery rates. BioVenic offers canine parvovirus therapeutic antibody development services, assisting in the development of effective therapeutic antibodies targeted at canine parvovirus, supporting your research and application in infected canine treatment. If you have development needs, feel free to contact us for more information.
References
- Jager, Mason C., et al. "Small but mighty: old and new parvoviruses of veterinary significance." Virology Journal 18 (2021): 1-29.
- Image retrieved from Figure 4 "Summary of parvovirus replication requirements. "Jager, Mason C., et al., 2021, used under [CC BY 4.0], the image title was changed to "Schematic diagram of CPV replication."